WSX15

WSX15 is a small molecule curcumin analog being developed by Canget BioTekpharma for the treatment of various solid tumors, including ovarian, lung, and colon cancers. As a synthetic derivative of curcumin, WSX15 is designed to overcome the pharmacological limitations of the natural compound, such as poor bioavailability and rapid metabolism, while enhancing its antineoplastic activity. The drug is currently in the preclinical stage, with in vitro studies demonstrating its potential efficacy against multiple cancer cell lines. The specific molecular targets and detailed mechanism of action have not been publicly disclosed by the sponsor.